Single-Dose Mucoadhesive Composition for Mucosal Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for ulcerative colitis and interstitial cystitis suffer from inefficiencies, including insufficient reduction of inflammation, frequent medication load, and rapid drug expulsion before therapeutic effect, leading to prolonged symptoms and recurrence.
Innovation Solution
A pharmaceutical composition comprising hyaluronic acid, chondroitin sulfate, sodium dihydrophosphate monohydrate, sodium phosphate anhydrous, sodium chloride, and a mucoadhesive biopolymer, designed for single-dose administration via catheter, enhancing adhesion to mucosal tissues to prolong exposure and therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory drugs (5-ASA, salicylates) are administered for ulcerative colitis, then inflammation is reduced, but adverse effects accumulate with continuous long-term therapy
Solution Approach 1:
The patent changes the chemical parameters by combining 5-ASA with hyaluronic acid in specific ratios (0.1-10 mg 5-ASA per 1 mg hyaluronic acid), creating a composite formulation that maintains anti-inflammatory efficacy while reducing adverse effects through the protective and reparative properties of hyaluronic acid
Solution Approach 2:
The patent creates a composite pharmaceutical composition combining two different substances (5-ASA and hyaluronic acid) with complementary mechanisms of action, where 5-ASA provides anti-inflammatory effects and hyaluronic acid provides mucosal protection and repair, thereby reducing overall toxicity while maintaining therapeutic efficacy
2Reliability
If rectally administered 5-ASA and HA therapy is used for severe colitis, then therapeutic benefit is increased, but drug residence time is insufficient leading to rapid expulsion
Solution Approach 1:
The patent uses hyaluronic acid as an intermediary substance that not only provides therapeutic benefit but also acts as a retention agent, forming a viscous matrix that slows drug expulsion and extends residence time in the rectum, thereby allowing sufficient contact time for therapeutic effect
Solution Approach 2:
The patent changes the physical parameters of the formulation by utilizing the viscous properties of hyaluronic acid to modify the flow and retention characteristics of the rectal administration, extending the duration of drug-mucosa contact without compromising the anti-inflammatory efficacy
3Reliability
If GAG replacement therapy is administered for interstitial cystitis, then bladder mucosa repair is promoted, but frequent urination causes rapid drug expulsion before therapeutic effect
Solution Approach 1:
The patent employs hyaluronic acid as a dual-function intermediary that serves both as the therapeutic agent for GAG replacement therapy and as a viscosity-modifying agent that retards urine flow and drug expulsion, thereby extending the exposure time of the bladder mucosa to the therapeutic composition despite frequent urination
Solution Approach 2:
The patent modifies the physical parameters of the instilled solution by utilizing the high viscosity and gel-forming properties of hyaluronic acid to slow urinary flow and increase residence time in the bladder, ensuring sufficient contact time for mucosal repair while maintaining the therapeutic GAG replacement effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides prolonged contact with mucosal tissues, reducing inflammation, accelerating healing, and minimizing recurrence by promoting tissue repair and regeneration, thereby improving clinical outcomes.
Implementation Method 1
a mucoadhesive biopolymer... enhancing adhesion to mucosal tissues to prolong exposure and therapeutic effect
Data Source
Figure 1~2
Figure 3~4
Figure 5~7
AI summary
Present invention relates to a pharmaceutical composition, which is suitable for use in the prevention, treatment, or alleviation of ulcerative colitis, and in the prevention, treatment, or alleviation of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Invention relates also to a medical device comprising the pharmaceutical composition in a package with leaflet.